Intracellular immune dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: state of the art and therapeutic implications (Q37082766)

18 August 2017

title

Intracellular immune dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: state of the art and therapeutic implications (English)

1 reference

18 August 2017

Jo Nijs

1

1 reference

18 August 2017

Marc Frémont

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

Expert Opinion on Therapeutic Targets

18 August 2017

published in

1 reference

18 August 2017

volume

12

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

281-289

1 reference

Immunologic aspects of chronic fatigue syndrome. Report on a Research Symposium convened by The CFIDS Association of America and co-sponsored by the US Centers for Disease Control and Prevention and the National Institutes of Health

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Chronic fatigue syndrome and fibromyalgia. Dilemmas in diagnosis and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

The 2–5 A system: Modulation of viral and cellular processes through acceleration of RNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Implications for RNase L in prostate cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Small self-RNA generated by RNase L amplifies antiviral innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Activation of NF-kappaB by double-stranded RNA (dsRNA) in the absence of protein kinase R and RNase L demonstrates the existence of two separate dsRNA-triggered antiviral programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

2',5'-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

69-kDa and 100-kDa isoforms of interferon-induced (2'-5')oligoadenylate synthetase exhibit differential catalytic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Activation of 2'-5' oligoadenylate synthetase by single-stranded and double-stranded RNA aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Enzymatic characteristics of recombinant medium isozyme of 2'-5' oligoadenylate synthetase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Diagnostic evaluation of 2′, 5′-oligoadenylate synthetase activities and antibodies against Epstein–Barr virus and Coxiella burnetii in patients with chronic fatigue syndrome in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Characterization of a 2',5'-oligoadenylate (2-5A)-dependent 37-kDa RNase L: azido photoaffinity labeling and 2-5A-dependent activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Increased neutrophil apoptosis in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Chronic fatigue syndrome: intracellular immune deregulations as a possible etiology for abnormal exercise response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Chronic fatigue syndrome: the fundamentals still apply

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Associations between bronchial hyperresponsiveness and immune cell parameters in patients with chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Chronic fatigue syndrome: exercise performance related to immune dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Impact of a maximal exercise test on symptoms and activity in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Increased daily physical activity and fatigue symptoms in chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Is a full recovery possible after cognitive behavioural therapy for chronic fatigue syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Complement activation in a model of chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Differential diagnosis of chronic fatigue syndrome and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

2-Methyladenosine-Substituted 2',5'-oligoadenylates: conformations, 2-5A binding and catalytic activities with human ribonuclease L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Inhibition of HIV type 1 replication in CD4 and CD14 cells purified from HIV type 1-infected individuals by the 2-5A agonist immunomodulator, 2-5A(N6B).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

Small-molecule activators of RNase L with broad-spectrum antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.12.3.281

10.1517/14728222.12.3.281

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference